lower pt better reflect
messag despit strong result manag lower guidanc due
estim impact exacerb fx fluctuat like
portion expect relat lost new patient start lower
procedur volum in-person offic visit neg impact sale ep henc
lower estim total revenu ep also lower pt
better reflect concentr challeng
face keytruda loe approach remain buy rate
revenu chang lower estim total revenu everi year
due increas competit dynam relat lost sales/delay demand
neg fx impact lower estim
respect product
chang includ lower gardasil revenu everi year vs previou
estim lower anim health revenu everi year remain bullish
keytruda overal sale growth competit increas keytruda
therapi see note competit intensifi potenti
novel mechan action anti-tigit novel regimen etc
estim global peak revenu keytruda peak
sale revenu concentr similar challeng humira
 chang lower ep estim
respect lower gross
margin accord manag guidanc maintain
sg margin result lower oper margin
across year peak oper margin decreas thereaft
assum patent expiri keytruda loss exclus per
guidanc estim fy ep line guidanc
estim total revenu lower end
compani guidanc due higher neg fx impact vs
mrk guidanc neg fx impact
page analyst certif import disclosur
pipelin updat today fda approv truda use addit
recommend dose mg everi week approv adult indic
keytruda addit typic mg everi three week dose believ
provid uniqu conveni advantag keytruda may uniqu benefici
current environ key pipelin potenti catalyst mention
dcf-base price target previous
ep forecast base averag dcf-base price
dcf-base price appli global pharma discount rate
termin growth rate cashflow
page analyst certif import disclosur
guggenheim partner llc estim compani guidanc progressionlin secur estsfactset consensu est report total sale fx impact total neg fx neg fx impactgross sg incom /expens expenseno oper expenseslow single-digit rate increaseslow singl digit rate rate non-gaap ep fx neg fx neg fx impact guggenheim partner llc estim compani pipelin potenti catalystsag moa indicationtrialpotenti catalyststock impactour viewtimingtruda small cell lung cancerphas lenvima rtk renal cell carcinomaphas mono/chemo bladder cancerphas select antagonist chronic cough adultsphas pivot inhibitor solid tumorsphas iitop-lin nasopharyng cancerphas top-lin vaccin valent pneumococc vaccin serotyp phase multipl studiestop-lin inhibitor multipl tumorsndrl list chinapotllabel inhibitor nsclc stage unresectablephas impactmarket viewpositivenegativemagnitud pipelin potenti catalyst pcd primari complet date global
downsid risk deceler gardasil growth neg keytruda readout
next month chang price environ oncolog drug
increas competit headwind keytruda franchis
page analyst certif import disclosur
usd million except ep
compani report guggenheim secur llc estim
page analyst certif import disclosur
